Here’s what you should know.
1. Abbott will divest two medical devices business used in cardiovascular work to gain FTC approval.
2. The FTC argued the two businesses would’ve harmed competition in United States markets for vascular closure devices.
3. Tokyo-based Terumo Corp. is acquiring St. Jude Medical’s and Abbott’s vascular closure device businesses. Terumo has dealt in a similar business in the U.S. for more than 30 years.
4. The FTC is requiring Abbott to notify the commission if it intends to acquire Advanced Cardiac Therapeutics’ lesion-assessing ablation catheter business. If it does, the FTC believes Abbott would have a monopoly in the arena.
More articles on turnarounds:
Olympus, Clinical Genomics & more— 4 GI company key notes
European ASC, emergency center services market to surge to $42.8B by 2020: 4 key points
What will happen to bundled payments during Donald Trump’s presidency?
